Pharmaceutical TechnologyOriginal article
J&J’s Imaavy secures expanded US approval in rare blood disorder
RegulatoryapprovedImaavyPositive
AI Analysis
Summary
J&J's Imaavy has received expanded FDA approval for use in a rare blood disorder, supporting the company's $5bn peak sales target for the drug.
Financial Highlights
Guidance
$5bn peak sales target
Outcome Details
Expanded US approval
Importance:6/10
Sentiment:
0.80
FDA approvalrare diseaselabel expansionJ&J
Related Companies
Read the original article
Published by Pharmaceutical Technology on August 25, 2026 3:38 PM